Bone Marrow Fibrosis

SAN DIEGO — Treatment with a selective PIM1 kinase inhibitor showed positive clinical reactions in a sample of 23 patients with relapsed/refractory myelofibrosis, according to preliminary data presented at ASH Annual Meeting.

Study results presented at Society of Hematologic Oncology Annual Meeting highlight the potential effect that socio-racial characteristics may have on outcomes of patients with primary myelofibrosis.